Results 61 to 70 of about 93,640 (252)
Diagnostic value of the impairment of olfaction in Parkinson's disease. [PDF]
PLoS ONE, 2013 Olfactory impairment is increasingly recognized as an early symptom in the development of Parkinson's disease. Testing olfactory function is a non-invasive method but can be time-consuming which restricts its application in clinical settings and ...
Swaantje Casjens +10 more
doaj +1 more source
Validity of a Wearable Digital Insole for Assessing Gait ON and OFF in Parkinson's Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Gait impairment is a distinctive symptom of Parkinson's disease that negatively impact mobility. We assessed the validity of wearable digital insoles against a validated reference gait analysis system for measuring select gait characteristics in patients with Parkinson's disease. Methods A comparative analysis between digital insoles
Deborah A. Hall +16 more
wiley +1 more source
Cells, 2019 Parkinson’s disease is associated with an increased risk of melanoma (and vice versa). Several hypotheses underline this link, such as pathways affecting both melanin and neuromelanin.
Dieter Leupold +9 more
doaj +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Cognitive decline is a disabling and variable feature of Parkinson disease (PD). While cholinergic system degeneration is linked to cognitive impairments in PD, most prior research reported cross‐sectional associations. We aimed to fill this gap by investigating whether baseline regional cerebral vesicular acetylcholine transporter ...
Taylor Brown +6 more
wiley +1 more source
A novel method for evaluating brain function and microstructural changes in Parkinson′s disease
Neural Regeneration Research, 2015 In this study, microstructural brain damage in Parkinson′s disease patients was examined using diffusion tensor imaging and tract-based spatial statistics.
Ming-fang Jiang +4 more
doaj +1 more source
Clinical Validation of Plasma p‐217tau in Neurological Diseases
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi +13 more
wiley +1 more source
DIAGNOSIS OF THE PARKINSON DISEASE BY USING DEEP NEURAL NETWORK CLASSIFIER
Electrica, 2017 Parkinson disease occurs when certain clustersof brain cells are unable to generate dopamine which is needed to regulate thenumber of the motor and non-motor activity of the human body.
Abdullah CALISKAN +3 more
doaj +2 more sources
CSF Monoamine Metabolites and Cognitive Trajectory in Early Parkinson's Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Imaging and postmortem studies indicate that abnormalities in monoaminergic neurotransmission contribute to cognitive impairment in Parkinson's disease (PD). However, it remains uncertain if cerebrospinal fluid (CSF) monoamine metabolites can serve as biomarkers of cognitive decline in early PD.
Jing‐Yu Shao +7 more
wiley +1 more source
The Identification of Alpha-Synuclein as the First Parkinson Disease Gene
Journal of Parkinson’s Disease, 2017 In this Commentary, I describe the events that led from an NINDS-sponsored Workshop on Parkinson Disease Research in 1995, where I was asked to speak about the genetics of Parkinson disease, to the identification a mere two years later of a mutation in ...
Robert L. Nussbaum
doaj +1 more source